- Home
- AMAL vs ORIC Comparison
AMAL vs ORIC Comparison
Compare AMAL & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | ORIC |
|---|---|---|
| Founded | 1923 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 837.3M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMAL | ORIC |
|---|---|---|
| Price | $40.50 | $9.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $36.00 | $19.73 |
| AVG Volume (30 Days) | 121.6K | ★ 1.4M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ 3.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.18 | N/A |
| Revenue Next Year | $6.55 | N/A |
| P/E Ratio | $12.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.13 | $4.52 |
| 52 Week High | $44.01 | $14.93 |
Technical Indicators
Market Signals| Indicator | AMAL | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 42.79 |
| Support Level | $36.50 | $9.33 |
| Resistance Level | $40.89 | $10.31 |
| Average True Range (ATR) | 1.29 | 0.59 |
| MACD | -0.26 | -0.02 |
| Stochastic Oscillator | 53.88 | 22.08 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.